CoChat

Targeting two‐pore domain K+channels TREK‐1 and TASK‐3 for the treatment of depression: a new therapeutic concept

Open access
Borsotto, M, Veyssiere, J, Moha ou Maati, H, Devader, C, Mazella, J, Heurteaux, C · 2015 · British Journal of Pharmacology
Cited by 63

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Depression is a disease that is particularly frequent, affecting up to 20% of the population in W estern countries. The origins of this pathology involve multiple genes as well as environmental and developmental factors leading to a disorder that remains difficult to treat. Several therapies for depression have been developed and these mainly target monoamine neurotransmitters. However, these treatments are not only associated with numerous adverse effects, but they are also ineffective for more than one‐third of patients. Therefore, the need to develop new concepts to treat depression is crucial. Recently, studies using knockout mouse models have provided evidence for a crucial role of two members of the two‐pore domain potassium channel (K 2P) family, tandem P‐domain weak inward rectifying K+(TWIK)‐related K+channel 1 (TREK‐1) and TWIK‐related acid‐sensitive K+channel 3 (TASK‐3) in the pathophysiology of depression. It is believed that TREK‐1 and TASK‐3 antagonists could lead to the development of new antidepressants. Herein, we describe the discovery of spadin, a natural peptide released from the maturation of the neurotensin receptor‐3 (also known as sortilin), which specifically blocks the activity of the TREK‐1 channel and displays particular antidepressant properties, with a rapid onset of action and the absence of adverse effects. The development of such molecules may open a new era in the field of psychiatry.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.12953

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 63

Metadata

Authors
Borsotto, M., Veyssiere, J., Moha ou Maati, H., Devader, C., Mazella, J., & Heurteaux, C.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2014-11-24
Volume
172
Issue
3
Pages
771-784
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2123932081
Cited by
63
References
9
FWCI
4.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting two‐pore domain K+channels TREK‐1 and TASK‐3 for the treatment of depression: a new therapeutic concept. https://app.cochat.ai/papers/10.1111/bph.12953
The paper
Borsotto, M., Veyssiere, J., Moha ou Maati, H., Devader, C., Mazella, J., & Heurteaux, C. (2015). Targeting two‐pore domain K+channels TREK‐1 and TASK‐3 for the treatment of depression: a new therapeutic concept. British Journal of Pharmacology. https://doi.org/10.1111/bph.12953

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.